|Articles|October 1, 2019
- Pharmaceutical Executive-10-01-2019
- Volume 39
- Issue 10
Pharmaceutical Executive, October 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive October 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Tech Tour for the C-Suite: Pharma’s Digital Futureover 6 years ago
It Starts with a Scribbleover 6 years ago
Olivier Laureau, Servier: Free to Grow, Innovateover 6 years ago
Corey McCann: A PDT Pioneerover 6 years ago
Data Shape-Up: Striving to Standardizeover 6 years ago
Policy Sync-Up: The Drug Importation Conundrumover 6 years ago
Validating Value Data: AI and Outcomesover 6 years ago
Underlying Platform: Data Unleashedover 6 years ago
Surfing the Wave: The Patient-Data Puzzleover 6 years ago
Where Does Europe’s Drug Industry Go from Here?Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5